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Abstract
Background Phospholipase A2 receptor (PLA2R) is rec-
ognized as a target antigen in primary membranous
nephropathy (MN); Anti-a-enolase antibody in primary
and secondary MN has been proposed, however, little is
known about the potential contribution of a-enolase to the
pathogenesis of MN.
Methods We evaluated circulating antibodies to a-eno-
lase by a dot blotting system and PLA2R by indirect
immunofluorescence, and glomerular deposition of these
proteins in 25 patients with primary MN, 20 patients with
secondary MN, 44 patients with collagen disease or severe
infection, 60 patients with nephritis (each ten patients of
IgA nephropathy, focal segmental gloemrulosclerosis,
minimal change nephrotic syndrome, membranoprolifera-
tive glomeurlonephritis, diabetic glomerulosclerosis, and
tubulointerstitial nephritis) as disease control, and 20
healthy subjects.
Results In primary MN, 18 of 25 sera (72 %) showed
anti-a-enolase antibody (IgG1 and IgG4, 11 pts; IgG4
alone, six pts; IgG1 alone, one pt). In secondary MN, 15 of
20 sera (75 %) contained anti-a-enolase antibody (IgG1
and IgG3, 13 pts; IgG3 alone, two pts). No circulating anti-
a-enolase antibody was found in 44 collagen diseases or
septic patients, 60 nephritis without MN, and 20 healthy
subjects. Twelve of 25 sera (48 %) from patients with
primary MN were positive for anti-PLA2R antibody,
whereas all patients with secondary MN were negative.
Eight of the 12 PLA2R-positive patients (67 %) with pri-
mary MN also had anti a-enolase antibody. Although
PLA2R antigen was present in a subepithelial pattern in 10
of 19 (52 %) patients with primary MN, a-enolase was
never detected in glomerular deposits in 19 and ten patients
with primary and secondary MN, respectively.
Conclusions Circulating anti-a-enolase antibodies are
highly present in both primary and secondary MN (about
70 %, respectively), while anti-PLA2R antibodies are
specific for primary MN (48 %) with a prevalence appar-
ently lower in the Japanese population than in Chinese and
Caucasian populations. The absence of a-enolase from
subepithelial immune deposits suggests that anti-a-enolase
antibodies do not contribute directly to immune-deposit
formation, although they may have other pathogenic
effects.
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Introduction
Membranous nephropathy (MN)—a major glomerular
disease and common cause of adult nephrotic syndrome—
is characterized by glomerular subepithelial IgG deposits
[1]. Primary MN is predominantly associated with
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glomerular deposition of the IgG4 subtype although vari-
able amounts of IgG1 were also detected in immune
deposits [2–6], whereas secondary MN is characterized by
prevailing deposits of IgG1, IgG2, and IgG3 [6–8]. During
the past decade, several breakthroughs have occurred with
the identification of several candidate human antigens in
MN. In infants with MN, Debiec et al. detected anti-neutral
endopeptidase antibodies that were produced by mothers
who lacked this enzyme [9, 10]. Beck et al. demonstrated
that IgG4 antibodies specific for M-type phospholipase A2
receptor (PLA2R) were present in glomerular eluates and
serum from adult patients with primary MN [11]. Other
candidate autoantigens in patients with primary MN
include superoxide dismutase 2 (SOD2), aldose reductase
[12] and a-enolase [13–15]. Debiec et al. reported that
some patients who develop MN in early childhood had
circulating anti-bovine serum albumin (BSA) antibodies
and cationic BSA as a component of glomerular immune
deposits [16]. Recently, Anti-thrombospondine type-1
domain-containing 7A antibody was reported in 10 % of
primary MN patients [17].
Interestingly, unlike other antibodies identified in
patients with autoimmune MN, anti-a-enolase antibodies
have been found in both primary and secondary MN [13,
14, 18]. In the present study, we examined the potential
relationship between circulating anti-a-enolase antibodies
and anti-PLA2R antibodies, and the glomerular deposition
of a-enolase and PLA2R proteins in Japanese patients with
primary and secondary MN.
Materials and methods
This study was approved by the Ethics Committee at Aichi
Medical University (10–127).
Patients’ characteristics
We included Japanese patients with MN who were
admitted to Aichi Medical University Hospital and affili-
ated hospitals between 2003 and 2011. Diagnosis of MN
was based on light microscopy, immunofluorescence, and
electron microscopy analyses of kidney biopsy specimens
[19]. Primary MN was defined according to morphologic
criteria after excluding known underlying diseases and
drug exposure. Sera from 25 patients with primary MN, 20
patients with secondary MN, 44 patients with collagen
diseases or severe infection, 60 patients with nephritis
without MN (each ten patients of IgA nephropathy, focal
segmental gloemrulosclerosis, minimal change nephrotic
syndrome, membranoproliferative glomeurlonephritis,
diabetic glomerulosclerosis, and tubulointerstitial
nephritis) as disease control, and 20 healthy subjects were
stored at -80 C until use. Sera from all patients with MN
were obtained before steroid and immunosuppressive
treatment with the approval of the institutional ethics
committee. Patients’ characteristics are summarized in
Tables 1 and 2. Complete remission was defined as urinary
protein excretion of less than 300 mg/day as a result of
therapeutic intervention such as prednisolone with or
without immunosuppressive drugs; spontaneous remission
was defined as complete remission in a patient receiving
anti-platelets or anti-hypertensive drugs only. Partial
remission was defined as proteinuria \3.5 g/day with a
decrease of proteinuria \50 % from baseline and
stable renal function.
Preparation of a-enolase deletion mutants
We obtained sequence encoding full-length human a-eno-
lase (433 amino acids; GenBank AK315417, Ensembl:
ENSG00000074800). As a result of post-translational
modification, human a-enolase is a 47-kDa glycoprotein.
Complementary DNA (cDNA) cloning and production of
fusion proteins were described elsewhere [20]. Briefly, full-
length and truncated cDNA encoding human a-enolase was
amplified in polymerase chain reactions, and ligated to
sequence encoding glutamine S-transferase (GST) (GE
Healthcare Bio-Sciences Corp., Piscataway, NJ). DNA was
cloned into pGEX plasmids and transformed into JM109
cells (Promega, USA), and protein expression was induced
using isopropyl-b-D-thiogalactopyranoside. After protein
extraction from JM109 cells, tagged proteins were affinity
purified using glutathione-Sepharose 4B (Amersham
Pharmacia Biotech).
Anti-a-enolase antibody by western and dot blot
analysis
Nitrocellulose membranes (GE Healthcare, UK) were
washed in PBS (Wako Pure Chemical Industries, Japan)
containing 10 lg/ml recombinant a-enolase protein and
5 % (w/v) skim milk (BD Difco, USA) for 60 min at room
temperature in non-reducing conditions. The membrane
was washed three times with PBS containing 0.05 %
Tween (Katayama Chemical Industries, Japan), and incu-
bated with patient serum at a dilution of 1:200. After three
washes in PBS containing 0.05 % Tween, the membrane
was incubated with horseradish peroxidase–conjugated
anti-human IgG antibodies at a dilution of 1:1000 (Sigma-
Aldrich, USA), and peroxidase–conjugated mouse mono-
clonal antibodies to human IgG1, IgG2, IgG3, IgG4 at a
dilution of 1:500 (Invitrogen, USA). After three washes,
reaction product on the membrane was visualized using an
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enhanced chemiluminescence system (ChemiLumit Kit,
GE Health Care, UK). Photographic images were obtained
using an LAS-1000 system (FujiFilm Co., Japan). Image
Reader Lite for LAS-1000 plus Ver. 1.3 (FujiFilm Co.) was
used to capture the images, which were edited using Adobe
Photoshop, when necessary.
Anti-PLA2R antibody by indirect
immunofluorescence
Anti-PLA2R specific autoantibody titers were measured as
previously described based on indirect immunofluores-
cence in HEK 293 cells that were transiently transfected
with full-length cDNA encoding PLA2R (Euroimmun)
[21]. Antibody positivity was defined as positive staining at
serum dilutions of at least 1/10. Negative results for anti-
PLA2R antibodies were defined as an absence of
detectable signals at an antibody dilution of 1/10.
Glomerular deposition of a-enolase and PLA2R
proteins
a-Enolase and PLA2R were detected in paraffin-embedded
native biopsies under a confocal microscope using affinity-
purified specific anti-rabbit a-enolase (AbD serotec) and
PLA2R antibodies (Atlas Antibodies, Stockholm, Sweden)
followed by goat Alexa 488 conjugated anti-rabbit IgG Fab
fragments (Molecular Probes, Eugene, OR, USA) as pre-
viously described [21]. Staining with only secondary anti-
bodies produced negative results for all biopsies.
Statistical analysis
Data were analyzed using Microsoft Excel software. Nor-
mally distributed variables were described as mean stan-
dard deviation and compared across primary and secondary
MN using analysis of variance. Age, amount of urinary

























MN-1 52 F I 2.60 3.0 0.52 Pos 1 ? 4 Pos 4 Pos PSL ? MZR
MN-2 74 M I to II 4.05 1.6 0.75 Pos 4 Pos 1 ? 4 Pos PSL ? MZR
MN-3 18 M I 1.41 3.5 0.38 Pos 1 ? 4 Neg Neg Na Dipyridamole
MN-4 77 M I 3.04 1.4 1.00 Neg Neg Pos 4 Na Unknown
MN-5 43 M I to II 6.86 2.8 0.69 Pos 1 ? 4 Neg Neg Na PSL ? MZR
MN-6 65 M III 0.58 4.1 0.85 Pos 1 Neg Neg Na PSL ? MZR
MN-7 70 M II to III 4.46 2.4 0.85 Pos 1 ? 4 Pos 4 Na PSL ? MZR
MN-8 75 F II 3.00 2.4 1.05 Pos 1 ? 4 Pos 1 ? 4 Na Unknown
MN-9 62 F I to II 0.62 2.9 0.48 Pos 1 ? 4 Neg Neg Pos ARB
MN-10 65 M I 4.16 2.4 0.88 Neg Neg Pos 4 Pos PSL ? MZR
MN-11 62 M II 3.40 2.7 0.79 Pos 4 Pos 4 Pos PSL ? MZR
MN-12 52 F I 5.00 1.9 0.59 Neg Neg Neg Neg Neg PSL ? MZR
MN-13 77 F I 3.15 1.3 0.57 Neg Neg Neg Neg Neg ARB
MN-14 61 F I 8.00 1.6 0.45 Neg Neg Pos 4 Pos Unknown
MN-15 69 M I to II 4.44 2.9 1.54 Pos 1 ? 4 Neg Neg Neg PSL ? MZR
MN-16 58 F I to II 1.10 3.8 0.44 Pos 4 Pos 4 Pos PSL ? MZR
MN-17 33 M I 1.16 3.2 0.72 Neg Neg Neg Neg Neg Unknown
MN-18 47 F I to II 2.62 2.7 0.77 Pos 1 ? 4 Neg Neg Neg PSL ? MZR
MN-19 69 F I 8.47 2.1 0.98 Pos 1 ? 4 Neg Neg Neg PSL ? MZR
MN-20 57 F I 1.24 1.8 0.97 Neg Neg Pos 1 ? 4 Pos PSL ? MZR
MN-21 73 M I to II 6.41 3.0 1.04 Pos 4 Pos 4 Pos ARB
MN-22 56 M II to III 0.30 3.4 0.68 Pos 1 ? 4 Neg Neg Neg Unknown
MN-23 65 M I 0.42 3.6 0.77 Pos 1 ? 4 Neg Neg Neg None
MN-24 68 M II 0.67 3.3 0.67 Pos 4 Neg Neg Neg ARB
MN-25 77 M I 1.82 2.8 0.92 Pos 4 Pos 4 Pos ARB
ARB angiotensin II receptor blocker, MN menbranous nephropathy, MZR mizoribin, na not available, PSL prednisolone, PLA2R AB anti-PLA2R
antibody
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protein, and serum creatinine were compared using Stu-
dent’s t test. Mann–Whitney U tests (nonparametric) were
used to compare results for anti-a-enolase antibody posi-
tivity in patients with MN and control subjects. All p val-




The study comprised 25 patients with primary MN, and 20
patients with secondary MN (seven patients had bucil-
lamine-induced nephropathy and 13 patients had lupus
nephritis World Health Organization type V). Patients’
characteristics are summarized in Tables 1 and 2. The
mean age of the patients with primary and secondary MN
was 61.0 ± 14.4 and 48.7 ± 16.3 years, respectively
(p\ 0.01). The mean serum creatinine level was
0.77 ± 0.25 and 0.67 ± 0.18 mg/dl (p = 0.07), and mean
proteinuria was 3.16 ± 2.39 g/day and 3.47 ± 3.13 mg/day
(p = 0.6), at the time of diagnosis in primary and secondary
MN, respectively. Treatment modalities were not known in
seven patients. One patient received dipyridamole alone, 29
patients were treated with prednisolone with or without other
immunosuppressants including Mizoribine (an immunosup-
pressive agent used in Japan), six patients were treated with
angiotensin II receptor blocker (ARB) alone, and two patients
received no therapy.
Detection of anti-a-enolase antibody
We first examined whether sera from patients with MN
contained antibodies specific for recombinant a-enolase.
Sera from 18 of 25 patients with primary MN (72 %)
were immunoreactive with a-enolase. Nine of 13
patients with lupus nephritis (World Health Organization
class V), (69 %) and six of seven patients with bucil-
lamine-induced MN (86 %) were positive for anti-a-
enolase antibodies (Fig. 1a). The inhibition tests showed
highly specific antibody to a-enolase (supplementary
materials 1). In contrast, sera from 44 collagen diseases
or septic patients, 60 nephritis without MN as disease
controls (Fig. 1b), and 20 healthy controls did not react
with a-enolase.


























LN-1 46 F lupus V 2.19 2.9 0.57 Pos 1 ? 3 Neg Neg Na PSL ? MZR
LN-2 54 F lupus V 4.32 2.5 0.69 Neg Neg Neg Neg Na PSL ? MZR
LN-3 58 M lupus V 3.23 2.4 0.74 Neg Neg Neg Neg Na PSL
LN-4 57 M lupus V 3.15 4.0 0.93 Neg Neg Neg Neg Na PSL ? TAC
LN-5 24 F lupus V 11.10 1.1 0.44 Pos 1 ? 3 Neg Neg Neg PSL
LN-6 40 F lupus V 5.69 2.5 0.50 Pos 1 ? 3 Neg Neg Neg PSL ? TAC
LN-7 18 F lupus V 3.34 1.7 0.85 Neg Neg Neg Neg Na PSL
LN-8 35 F lupus V 0.52 3.7 0.53 Pos 1 ? 3 Neg Neg Neg None
LN-9 49 M lupus V 1.44 2.6 1.00 Pos 1 ? 3 Neg Neg Neg PSL ? MZR
LN-10 42 F lupus V 3.07 2.4 0.69 Pos 3 Neg Neg Neg PSL
LN-11 19 F lupus V 0.13 4.4 0.81 Pos 1 ? 3 Neg Neg Neg Unknown
LN-12 42 F lupus V 1.23 2.6 0.48 Pos 1 ? 3 Neg Neg Neg PSL ? MZR
LN-13 47 F lupus V 0.10 4.3 0.52 Pos 1 ? 3 Na Na Neg PSL
BUC-1 56 F I to II 3.08 3.2 0.46 Pos 1 ? 3 Neg Neg Na PSL ? MZR
BUC-2 52 M I 2.46 2.4 0.58 Pos 1 ? 3 Neg Neg Na PSL
BUC-3 69 M I to II 8.94 3.2 0.99 Pos 3 Neg Neg Na PSL
BUC-4 70 M I 2.00 3.1 0.78 Pos 1 ? 3 Neg Neg Na PSL ? ARB
BUC-5 63 M I to II 3.68 1.9 0.65 Pos 1 ? 3 Neg Neg Na ARB
BUC-6 53 M I 0.30 3.7 0.50 Pos 1 ? 3 Neg Neg Neg PSL
BUC-7 79 M I 9.50 1.6 0.72 Neg Neg Neg Neg Neg Unknown
ARB angiotensin II receptor blocker, BUC bucillamine, LN lupus nephritis, MN menbranous nephropathy, MZR mizoribin, na not available, PSL
prednisolone, TAC tacrolimus
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IgG subclasses of circulating anti-a-enolase
antibodies
We then characterized IgG subclasses of anti-a-enolase
antibodies in both primary and secondary MN (Fig. 2). In
primary MN, most antibodies appeared to be IgG1 or IgG4;
72 % of patients being positive for at least one of these
subclasses on dot blots. In secondary MN, however, IgG1
and IgG3 produced the strongest signals, with positive
results observed in 75 % of patients, contrasting very little
or absent IgG4 reactivity. Serum from each patient that
immunoreacted with full-length a-enolase also was posi-
tive with the N- and C-terminal fragments (amino-acid
stretch 1–66 and 349–433, respectively) (supplementary
materials 2-5). Further to test whether the N- and C-termini
have closely related epitopes, we blocked reactivity to the
N-terminal fragment with the C-terminal fragment and
conversely. The results suggest that the epitope/s at the
both ends of protein are partially related. However, further
studies are necessary to identify an exact epitope (or epi-
topes) recognized by circulating antibodies.
Circulating anti-a-enolase antibodies
before and after treatment
We examined the effects of treatment on circulating anti-
bodies specific for a-enolase in a patient with primary MN, a
patient with lupus MN, and three patients with bucillamine-
induced MN, who all attained complete remission after
treatment. We also assessed three patients with primary MN
and one patient with lupus MN who failed to achieve com-
plete remission despite therapy. Notably, circulating anti-
bodies were no longer detected in each of the patients who
reached complete remission (Fig. 3). Among the 4 patients
who failed to attain complete remission, antibody titers were
markedly decreased in the patient with lupus MN, and in two
of three patients with primary MN, and unchanged in the
remaining patient with prevailing IgG1 (Fig. 3).
Anti-PLA2R antibody
Twelve of 25 (48 %) tested sera from patients with primary
MN had anti-PLA2R antibodies (Table 1). Of the 12
PLA2R-positive patients, 8 were positive for anti-a-eno-
lase, 4 were negative. Of the 13 PLA2R-negative patients,
10 were positive for anti-enolase. None of the 19 examined
patients with secondary MN were positive for anti-PLA2R
antibodies (Table 2).
Glomerular deposition of PLA2R and a-enolase
proteins
In paraffin-embedded kidney biopsy specimens, confocal
microscopy showed the presence of PLA2R in subepithelial
Fig. 1 Immunoreactivity observed with full-length a-enolase in dot
blot assays. a Sera from 18 of 25 patients (72 %) with primary MN
immunoreacted with a-enolase. Nine of 13 patients with lupus
nephritis (World Health Organization class V), (69 %) and 6 of seven
patients with bucillamine-induced MN (86 %) were positive for anti-
a-enolase antibodies. b Left line primary membranous nephropathy
MN4 and MN10 were negative, and MN8 and MN 18 were positive.
lupus nephritis LN4 and LN8 was negative and positive, respectively.
bucillamine-induced MN BUC5 was positive and BUC7 was
negative. Right side lanes included each ten patients with tubuloin-
terstitial nephritis (TIN), diabetic glomerulosclerosis (DM), membra-
noproliferative glomerulonephritis (MPGN), focal segmental
glomerulosclerosis (FSGS), IgA nephropathy (IgA), and minimal
change nephrotic syndrome (MC), which were all negative
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deposits along glomerular capillary loops (Figs. 4a, 5a) in
10 of 19 patients with primary MN. Nine of the ten patients
also had circulating anti-PLA2R antibodies (Table 1).
PLA2R was absent in the 10 examined biopsy specimens
from patients with lupus- and bucillamine-related MN
(Fig. 4b, c).
a-enolase was strongly expressed in tubular epithelium and
was weak positive in glomerular parietal cells (Fig. 4d, e, f)
and very weakly detected in the cytoplasm of glomerular cells
on high magnification (Fig. 5b), but unlike PLA2R, a-enolase
was never detected in subepithelial deposits in the 29 biopsy
specimens where this was examined (Fig. 5b). The pattern of
expression for a-enolase was the same in all groups, irre-
spective of the presence or absence of circulating anti a-
enolase antibodies. Human IgG-adsorbed primary and sec-
ondary antibodies tested on frozen sections gave no signal in
glomeruli but still well visible staining in proximal tubules
(supplementary materials 6).
Discussion
Our study provides important data on immunopathology of
MN. It first shows that circulating anti-a-enolase IgG4
antibodies, with or without IgG1 antibodies, were present
in 72 % of the patients with primary MN, while anti-a-
enolase IgG3 antibodies, with or without IgG1 antibodies,
were detected in 75 % of those with secondary MN. Cir-
culating antibodies disappeared in the few tested patients
undergoing complete remission. Second, we showed a low
prevalence (48 %) of anti-PLA2R antibodies in this small
cohort of Japanese patients with primary MN assessed
before treatment, with eight of 25 patients producing both
antibodies (32 %), while we could not detect anti-PLA2R
antibodies in secondary MN such as bucillamine-induced
MN where they had not been searched as yet. Third, we
could not detect a-enolase in subepithelial immune
deposits in any of the patient with circulating anti-a-eno-
lase antibodies, which questions their role in the patho-
genesis of MN, including PLA2R -unrelated MN, whereas
PLA2R was detected in the deposits in all nine tested
patients with anti-PLA2R antibodies and in one patient
without circulating antibodies.
Anti-a-enolase antibodies have been reported in patients
with a large variety of autoimmune and inflammatory
diseases such as systemic lupus erythematosus (SLE),
rheumatoid arthritis (RA), and autoimmune mediated
retinopathy (AR) [22], with a prevalence of 21, 25 %, and
about 30 %, respectively [23–25]. Based on our results and
those from Wakui et al. approximately 70 % patients with
Fig. 2 Circulating anti-a-enolase IgG antibody subclasses in primary
and secondary MN. Upper left IgG1 subclass, upper right IgG2
subclass, lower left IgG3 subclass, lower right IgG4 subclass. For
primary MN, most antibodies appeared to be IgG1 or IgG4; 72 % of
patients were positive for at least one of these subclasses on dot blots.
For secondary MN, however, IgG1 and IgG3 produced the strongest
signals, with positive results observed in 75 % of patients
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primary or secondary MN carry anti-a-enolase antibodies
[13]. We detected mostly IgG4 and IgG1 anti-a-enolase
antibodies in primary MN, and IgG3 and IgG1 anti-a-
enolase antibodies in secondary MN, while Wakui et al.
predominantly identified IgG1 and IgG3 anti-a-enolase
antibodies. These discrepancies might be due to different
affinities of the anti-subclass antibodies used for detection.
More recently, Bruschi et al. found that anti-a-enolase
IgG4 antibody levels were high in only 25 % of patients
with primary MN [14]. The different prevalence of anti-a-
enolase antibodies between Japanese and Italian popula-
tions may reflect underlying genetic factors, including
human leukocyte antigen polymorphisms. Although anti
a-enolase antibodies were reported to be detected in sera
of healthy subjects [26, 27], we could not detect
anti-a-enolase antibodies in disease controls including
those with connective disease like Bruschi et al. [14]. One
possible explanation of this discrepancy might be the
technical approaches and their different sensitivity and
specificity.
Because of the apparently wide spectrum of diseases
associated with anti-a-enolase antibodies, these antibodies
by themselves cannot help for the diagnosis of specific
autoimmune diseases. Therefore determination of
immunoreactive sequences of a-enolase associated with
disease-specific pathogenic autoantibodies is of great
importance. Epitope mapping performed in cancer-associ-
ated retinopathy (CAR) showed the epitope located
between amino-acids 56 and 63 (56–63aa) being specifi-
cally associated with pathogenic sera [28]. In endometrio-
sis, anti- a-enolase antibodies bound to two epitopes at
53–87aa and 207–238aa and shared reactivity against the
epitope 56–63aa with CAR patients [29]. The epitope for
pathogenic antibodies in Hashimoto’s encephalopathy is
located in the N-terminal part of a-enolase protein [30]. In
our patients, antibodies bound to epitopes located in the first
66aa at the N-terminal end and in the last 84aa at the
C-terminal end of the protein. The next step will be to
perform fine epitope mapping of these regions, and to
investigate the pathogenic relevance of these epitopes.
a-Enolase is an ubiquitous cytoplasmic glycolytic
enzyme involved in the synthesis of pyruvate [31]. In
addition to its glycolytic function, this 47-kDa glycoprotein
exerts many other functions related to its subcellular
location [31]. Different cellular localizations of potential
MN auto-antigens are seen under normal physiologic
conditions. While neutral endopeptidase and PLA2R are
expressed on cell surface of podocytes [9, 11, 32], aldose
reductase and SOD2 are cytoplasmic/mitochondrial
enzymes which can be enhanced at the cell surface after
oxidative stress [12]. Similarly, a-enolase is usually cyto-
plasmic but its expression varies according to the cell
conditions and can be expressed at the surface of many
eukaryotic cells [31].
Although circulating anti-a-enolase antibodies were
commonly found, unlike PLA2R, a-enolase was never
detected in subepithelial immune deposits, in contrast with
the observations made by Bruschi et al. [14]. We used
human IgG-adsorbed primary and secondary antibodies
tested on frozen sections gave no signal of a-enolase in
glomeruli but still well visible staining in proximal tubules.
This finding suggests that anti-a-enolase antibody does not
directly contribute to the formation of subepithelial
immune deposits and resulting complement activation. We
cannot, however, exclude a pathogenic role for anti-a-
enolase antibodies through binding to endothelial or
podocyte cell surface, and subsequent alteration of cell
functions. Alterations induced by binding of anti-a-enolase
Fig. 3 Circulating antibodies specific for a-enolase before and after
treatment for MN. a The complete remission group contains sera from
primary MN-5 and secondary MN (lupus nephritis-6, and bucillamine
-1, -2, 3). In MN-5, signals for IgG1 and IgG4 became negative.
Signals for IgG1 and IgG3 were no longer detected in all secondary
MN patients after treatment. b The partial remission group contains
sera from primary MN-2, -6, -18, and secondary MN (lupus nephritis-
1). In MN-2, IgG4 antibody is still present, albeit with a reduced
intensity. In MN-6, strong signals for IgG1 were shown before
treatment, and remained unchanged after treatment. In MN-18, the
signals for IgG1 and IgG4 were still positive, but with reduced
intensity. In LN-1, antibodies of the IgG3 subclass were not observed
after treatment. Lanes ‘‘f’’ and ‘‘g’’ are the 1142F and the 295R
fragments of a-enolase, respectively
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antibodies to the surface of endothelial cells or podocytes
may increase permeability of the capillary wall, leading to
enhanced access and accumulation of pathogenic antibod-
ies such as anti- PLA2R. Furthermore, because a-enolase
has pleiotropic effects, antibodies may perturb other
important cellular functions. For instance, anti-a-enolase
antibodies were shown to inhibit the binding of plas-
minogen to a-enolase on cell surface, which means
protective effects from proteolytic activities of plasmin
[33, 34]. On the contrary, intracellular anti-a-enolase
antibodies taken-up by endocytosis may interfere with
glycolysis, decrease cellular ATP levels, and increase
intracellular Ca2?, which ultimately may induce apoptosis
[35].
We found that the prevalence of anti-PLA2R antibodies
in previously untreated patients (48 %) was lower than that
Fig. 4 Glomerular deposition of PLA2R and a-enolase proteins in
primary and secondary MN analyzed by confocal microscopy. PLA2R
was present in primary MN (a), but not in secondary MN due to lupus
nephritis (LN) and bucillamine (BUC) (b, c). a-enolase was strongly
expressed in tubular epithelium and was weak positive in glomerular
parietal cells (d, e, f), but was not detected in subepithelial deposits
along glomerular capillary loops as was shown for PLA2R in primary
MN
Fig. 5 High magnification of
PLA2R and a-enolase proteins
in primary MN. PLA2R was
detected in subepithelial
deposits along glomerular
capillary loops (a) whereas a-
enolase was never detected in
subepithelial deposits (b)
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previously reported in Caucasian, African, and Chinese
cohorts [11, 36–38], suggesting an effect of the genetic
background. Akiyama et al. reported similar data that 53 %
of patients with idiopathic MN in Japan [39].
In conclusion, circulating anti-a-enolase antibody was
detected in about 70 % of patients with both primary and
secondary MN, while anti-PLA2R antibody was restricted
to primary MN. The absence of glomerular deposition of a-
enolase in subepithelial area contrasting with the presence
of PLA2R in immune deposits, suggests that instead of
being implicated in the formation of immune deposits, anti-
a-enolase antibody binding to glomerular cell surface
might increase access to the podocyte of other antibodies
such as anti-PLA2R, and thus be an enhancing event in
primary and secondary MN. Further studies on larger
cohorts are needed to confirm this hypothesis and to
delineate the value of anti-a-enolase antibody as biomarker
for diagnosis and monitoring of MN patients and of a-
enolase as potential therapeutic target.
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